Safety and Efficacy of PD-1 Antibody SHR-1210 Combined with Concurrent Chemoradiotherapy to Treat Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase Ib Clinical Trial

Abstract

There were no significant differences in patient characteristics by treatment group in both test and validation cohorts, including age, gender, race, histology, stage, location in the esophagus, radiation dose, and comorbidities. Neoadjuvant chemoradiation costs were higher for PBT vs.